Global Heparin Market to Reach USD 5.58 Billion in 2022, Expected to Grow at 5.5% CAGR During Forecast Period

Government support for healthcare and growing R&D activities are key drivers of market growth

The global heparin market, valued at USD 5.58 billion in 2022, is set to experience steady growth with a projected compound annual growth rate (CAGR) of 5.5% during the forecast period. This growth is driven by increasing government investments in healthcare infrastructure and rising research and development efforts to enhance the therapeutic potential of heparin while minimizing its side effects.

Download Free Exclusive Sample PDF@ https://www.emergenresearch.com/request-sample/2544

Heparin, commonly known as Unfractionated Heparin (UFH), is a naturally occurring anticoagulant (blood thinner) widely used in medical treatments. It plays a crucial role in preventing blood clots and is essential in treating conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE), which affect approximately 900,000 people annually in the U.S., according to the Centers for Disease Control and Prevention (CDC).

Key Drivers of Heparin Market Growth

One of the primary factors driving the heparin market's growth is the increasing prevalence of chronic conditions such as cardiovascular diseases, kidney diseases, and inflammatory disorders. These conditions are often linked to lifestyle factors such as obesity, poor diet, smoking, and excessive alcohol consumption. The demand for anticoagulants like heparin is further fueled by the rising incidence of coagulation disorders, including hemophilia, von Willebrand disease, and clotting factor deficiencies.

According to CDC data from 2020, around 400 babies are born with hemophilia annually in the U.S., highlighting the growing need for heparin in managing blood clotting disorders. Similarly, approximately 900,000 Americans suffer from venous thromboembolism (VTE), a condition that often requires heparin-based treatments.

Challenges Facing the Market

Despite its widespread use, heparin is not without risks. One notable side effect is Heparin-Induced Thrombocytopenia (HIT), a potentially serious condition that can lead to low platelet counts. This risk presents a challenge for the market, as physicians must carefully monitor patients using heparin, especially during surgeries where blood clotting plays a critical role. However, these side effects have not deterred its use in critical medical procedures, and the market continues to grow.

Product Segmentation

The global heparin market is segmented by product type into Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), and others. In 2022, the UFH segment held the largest market share, driven by its effectiveness in treating chronic diseases and its use in blood transfusions. UFH acts quickly by enhancing the body's natural ability to inhibit clotting factors. Its short half-life, low cost, and safety profile make it a preferred option in situations where rapid and reversible anticoagulation is necessary.

Though long-term use of UFH carries the risk of thrombocytopenia, studies show that this side effect is rare. For instance, in a recent trial, only 0.32% of patients treated with UFH for acute pulmonary embolism developed thrombocytopenia.

Heparin Type Insights

By type, the market is categorized into heparin calcium, heparin sodium, and others. The heparin calcium segment is expected to show rapid growth during the forecast period. Heparin calcium is derived from natural sources and is a key ingredient in anticoagulants that inhibit enzymes responsible for blood clotting. This makes it a vital component in managing coagulation disorders.

End-User Segment Insights

The market is further divided by end-user into hospitals, clinics, and ambulatory surgical centers (ASCs). Hospitals accounted for the largest share of the market in 2022 due to the increasing number of patient admissions requiring heparin treatments. Hospitals also act as primary distribution points for heparin, especially in surgeries, kidney dialysis, and other critical care applications where anticoagulation is essential.

Interested in knowing more relevant information? Click here: https://www.emergenresearch.com/industry-report/heparin-market

Heparin Top Companies and Competitive Landscape

The global heparin market is fairly fragmented with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, and developing, testing, and introducing more effective heparin solutions.

Some major players included in the global heparin market report are:

Baxter International Inc.
OPOCRIN GROUP
Pfizer Inc.
Aspen Pharmacare Holdings Limited
B Braun Melsungen AG
Leo Pharma AS
GLAND PHARMA
Smiths Medical
Novartis AG
HIKMA PHARMACEUTICALS

Heparin Latest Industry Updates

On 9 June 2020, Gland Pharma Ltd. along with its partners MAIA Pharmaceuticals Inc. and Athenex Pharmaceutical Division launched a ready to use Bivalirudin injection in US, which is the first on-frozen ready to use bivalirudin 505b (2) NDA approved by the U.S.

On 6 January 2022, Optimvia which is biotechnology company specializing in engineering enzymes and cofactors for the synthesis of complez therapeutic molecules collaborated with Ginko Bioworkds, which is one of the leading horizontal platform for cell programming. Through this collaboration, the companies will improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently being produced from industrial animal agriculture.
Heparin Market Segmentation Analysis

For the purpose of this report, Emergen Research has segmented the global heparin market on the basis of product, type, application, end-use, and region:

Product Outlook (Revenue, USD Billion; 2019-2032)

Unfractionated Heparin (UFH)
Low Molecular Weight Heparin (LMWH)
Others

Type Outlook (Revenue, USD Billion; 2019-2032)

Heparin calcium
Heparin sodium
Others

Application Outlook (Revenue, USD Billion; 2019-2032)

Stroke
Vein thromboembolism
Others

End-Use Outlook (Revenue, USD Billion; 2019-2032)

Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)

Make Payment [Buy your Exclusive copy] @ https://www.emergenresearch.com/select-license/2544

Regional Outlook (Revenue, USD Billion; 2019-2032)

North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Benelux
Russia
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
ASEAN Countries
Oceania
Rest of APAC
Latin America
Brazil
Mexico
Rest of LATAM
Middle East & Africa
GCC Countries
Israel
Turkey
South Africa
Rest of Middle East & Africa

Contact Us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.